Lyme Disease vaccine candidate: Final Phase 2 study initiated
by Press Release from Outbreak News Today on (#5F4G6)
Valneva SE and Pfizer Inc. announced Monday the initiation of study VLA15-221. The VLA15-221 study builds on previous positive Phase 2 studies, incorporates new dose regimens and is anticipated to be the final Phase 2 study readout before a decision to progress into pivotal Phase 3 studies. VLA15-221 is a randomized, observer-blind, placebo-controlled Phase 2 [...]
The post Lyme Disease vaccine candidate: Final Phase 2 study initiated appeared first on Outbreak News Today.